EyeD raises € 28M from a syndicate of investors amongst which Qbic II

Qbic II is happy to announce its participation in the € 28M funding round of EyeD pharma, a Belgian biotech company working to improve the treatment options available to Glaucoma patients. Related press coverage can be found via the following links:

De Tijd: https://www.tijd.be/ondernemen/farma-biotech/28-miljoen-euro-voor-luiks-oogimplantaat/10129226.html

L’Echo: https://www.lecho.be/entreprises/pharma-biotechnologie/la-biotech-eyed-pharma-leve-28-millions/10129228.html